Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure

Hypertension

Volumn 59, Issue 2 SUPPL. 1, 2012, Pages 477-484

  Yu, Yang ^a   Zhang, Zhi Hua ^a   Wei, Shun Guang ^a   Weiss, Robert M ^a,b   Felder, Robert B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

autonomic regulation; nuclear factor B; peroxisome proliferator activated receptor , proinflammatory cytokines; renin angiotensin system

Indexed keywords

APELIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; ANGIOTENSIN 1 RECEPTOR; NORADRENALIN;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DNA BINDING; GANGLION BLOCK; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT VENTRICLE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; LUNG WEIGHT; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; EATING; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; ANIMAL CELL; ANIMAL TISSUE; CYTOKINE PRODUCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DP-DT; PROTEIN DNA BINDING; SHAM PROCEDURE; SYMPATHETIC INNERVATION;

ANIMALS; BODY WEIGHT; CYTOKINES; EATING; HEART FAILURE; INFLAMMATION; MALE; MODELS, ANIMAL; NF-KAPPA B; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES;

EID: 84856100802     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.182345     Document Type: Conference Paper

References (62)

1. Patel KP. Role of paraventricular nucleus in mediating sympathetic outflow in heart failure. Heart Fail Rev. 2000;5:73-86. (Pubitemid 30301512)
2. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, Johnson AK. Heart failure and the brain: New perspectives. Am J Physiol Regul Integr Comp Physiol. 2003;284:R259-R276. (Pubitemid 36120141)
3. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol. 2009;297:H1557-H1566.
4. Westcott KV, Huang BS, Leenen FH. Brain renin-angiotensin-aldosterone system and ventricular remodeling after myocardial infarct: A review. Can J Physiol Pharmacol. 2009;87:979-988.
5. Infanger DW, Cao X, Butler SD, Burmeister MA, Zhou Y, Stupinski JA, Sharma RV, Davisson RL. Silencing Nox4 in the paraventricular nucleus improves myocardial infarction-induced cardiac dysfunction by attenuating sympathoexcitation and periinfarct apoptosis. Circ Res. 2010;106: 1763-1774.
6. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-α agonists. Front Biosci. 2008;13: 1813-1826. (Pubitemid 351599735)
7. Yu Y, Zhang ZH, Wei SG, Chu Y, Weiss RM, Heistad DD, Felder RB. Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. Circ Res. 2007;101:304-312. (Pubitemid 47344080)
8. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension. 2008;51:727-733. (Pubitemid 351301527)
9. Wei SG, Yu Y, Zhang ZH, Weiss RM, Felder RB. Angiotensin II-triggered p44/42 mitogen-activated protein kinase mediates sympathetic excitation in heart failure rats. Hypertension. 2008;52:342-350.
10. Huang BS, Ahmad M, Tan J, Leenen FH. Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2009;297: H968-H975.
11. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferatoractivated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166. (Pubitemid 27290462)
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorα(PPARγ). J Biol Chem. 1995;270:12953-12956.
13. Mendez M, LaPointe MC. PPARγ inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension. 2003;42:844-850. (Pubitemid 37237334)
14. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res. 2000;87:596-602.
15. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, Nasr H, Loftus IM, Thompson MM, Cockerill GW. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-3132.
16. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor γactivators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
17. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease. Endocr J. 2010;57:847-852.
18. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferatoractivated receptorβregulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension. 2006;47:102-108. (Pubitemid 43177822)
19. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 2000; 101:1165-1171. (Pubitemid 30146619)
20. Lee TM, Chou TF. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol. 2003;285:H1650-H1659.
21. Suzuki G, Khanal S, Rastogi S, Morita H, Mishima T, Anagnostopoulos PV, Nass O, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN. Long-term pharmacological activation of PPARγ does not prevent left ventricular remodeling in dogs with advanced heart failure. Cardiovasc Drugs Ther. 2007;21:29-36. (Pubitemid 46594985)
22. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-α: Therapeutic target for ischemic stroke. Trends Pharmacol Sci. 2007;28:244-249. (Pubitemid 46661003)
23. Nicolakakis N, Hamel E. The nuclear receptor PPARγ as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci. 2010;2:21.
24. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator-activated receptor γ in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology. 2010;58:337-345.
25. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW. Expression of peroxisome proliferator-activated receptor-α in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology. 2009;150:707-712.
26. Chan SH, Wu KL, Kung PS, Chan JY. Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-α and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension. 2010;55:1444-1453.
27. American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol. 2002;283:R281-R283.
28. Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J. The intracerebral application of the PPARβ-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci. 2005;22: 278-282. (Pubitemid 41059994)
29. Glatz T, Stock I, Nguyen-Ngoc M, Gohlke P, Herdegen T, Culman J, Zhao Y. Peroxisome-proliferator-activated receptors γ and peroxisomeproliferator- activated receptors β/δand the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens. 2010;28:1488-1497.
30. Yu Y, Kang YM, Zhang ZH, Wei SG, Chu Y, Weiss RM, Felder RB. Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: Role of nuclear factor kappaB. Hypertension. 2007;49:511-518.
31. Zhang ZH, Yu Y, Wei SG, Nakamura Y, Nakamura K, Felder RB. EP3 receptors mediate PGE2-induced hypothalamic paraventricular nucleus excitation and sympathetic activation. Am J Physiol Heart Circ Physiol. 2011;301:H1559-H1569.
32. Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe J. Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor γtranscriptional activity in vascular smooth muscle cells. Circ Res. 2009; 104:69-78.
33. Kleiber AC, Zheng H, Sharma NM, Patel KP. Chronic AT1 receptor blockade normalizes NMDA-mediated changes in renal sympathetic nerve activity and NR1 expression within the PVN in rats with heart failure. Am J Physiol Heart Circ Physiol. 2010;298:H1546-H1555.
34. Kang YM, Ma Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: Role of nuclear factor-kappaB. Cardiovasc Res. 2008;79:671-678.
35. Park SJ, Lee KS, Kim SR, Min KH, Choe YH, Moon H, Chae HJ, Yoo WH, Lee YC. Peroxisome proliferator-activated receptor γ agonist downregulates IL-17 expression in a murine model of allergic airway inflammation. J Immunol. 2009;183:3259-3267.
36. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci. 1999;55: 932-943. (Pubitemid 29304447)
37. Jiang C, Ting AT, Seed B. PPAR-α agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86. (Pubitemid 28079219)
38. Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY, Shyue SK, Chen JJ, Chen YE, Maeda N, Wu KK, Lin TN. Ligand-activated peroxisome proliferator-activated receptor-α protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 γupregulation. Circulation. 2009;119:1124-1134.
39. Beyer AM, de Lange WJ, Halabi CM, Modrick ML, Keen HL, Faraci FM, Sigmund CD. Endothelium-specific interference with peroxisome proliferator activated receptor γcauses cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103:654-661.
40. Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE. Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappaβ. J Cell Biochem. 2003;90:732-744. (Pubitemid 37392464)
41. Ruan H, Pownall HJ, Lodish HF. Troglitazone antagonizes tumor necrosis factor-α -induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem. 2003;278:28181-28192. (Pubitemid 36900018)
42. Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-kappaB and C/EBP. Blood. 2007;110: 4373-4384. (Pubitemid 351377804)
43. Zand H, Rahimipour A, Salimi S, Shafiee SM. Docosahexaenoic acid sensitizes Ramos cells toβ-irradiation-induced apoptosis through involvement of PPAR-α activation and NF-kappaB suppression. Mol Cell Biochem. 2008;317:113-120.
44. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension. 1996;27:1009-1017. (Pubitemid 26113850)
45. Cowling RT, Gurantz D, Peng J, Dillmann WH, Greenberg BH. Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-α or interleukin-1β. J Biol Chem. 2002;277: 5719-5724. (Pubitemid 34968348)
46. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38: 1654-1661. (Pubitemid 43947653)
47. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405-455.
48. Ogawa K, Hirooka Y, Kishi T, Sunagawa K. Brain AT1 receptor activates the sympathetic nervous system through Toll-like receptor 4 in mice with heart failure. J Cardiovasc Pharmacol. 2011;58:543-549.
49. Felder RB, Yu Y, Zhang ZH, Wei SG. Pharmacological treatment for heart failure: A view from the brain. Clin Pharmacol Ther. 2009;86: 216-220.
50. Lazartigues E, Sinnayah P, Augoyard G, Gharib C, Johnson AK, Davisson RL. Enhanced water and salt intake in transgenic mice with brain-restricted overexpression of angiotensin (AT1) receptors. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1539-R1545.
51. Camargo LA, Saad WA, Simoes S, Santos TA. Interaction between paraventricular nucleus and septal area in the control of physiological responses induced by angiotensin II. Braz J Med Biol Res. 2002;35: 1017-1023. (Pubitemid 35452881)
52. Johnson AK, Thunhorst RL. The neuroendocrinology of thirst and salt appetite: Visceral sensory signals and mechanisms of central integration. Front Neuroendocrinol. 1997;18:292-353. (Pubitemid 27297557)
53. DiBona GF. Physiology in perspective: The wisdom of the body-neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005; 289:R633-R641. (Pubitemid 41208425)
54. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406-416.
55. Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2005;70:53-62. (Pubitemid 41207648)
56. Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ. A role for central nervous system PPAR-α in the regulation of energy balance. Nat Med. 2011;17:623-626.
57. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf. 2009;8:15-32.
58. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010;56:297-303.
59. Gao L, Wang WZ, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: Potential mechanism for sympathetic overactivity in heart failure. Hypertension. 2008;52:708-714.
60. Lindley TE, Infanger DW, Rishniw M, Zhou Y, Doobay MF, Sharma RV, Davisson RL. Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction. Am J Physiol Regul Integr Comp Physiol. 2009;296: R1-R8.
61. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature. 2010;466:451-456.
62. Houtkooper RH, Auwerx J. Obesity: New life for antidiabetic drugs. Nature. 2010;466:443-444.